Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pacemaker, Artificial | 4 | 2024 | 50 | 2.980 |
Why?
|
| Catheter Ablation | 6 | 2026 | 160 | 1.770 |
Why?
|
| Atrial Fibrillation | 8 | 2026 | 884 | 1.340 |
Why?
|
| Thromboembolism | 3 | 2024 | 74 | 0.940 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2025 | 6 | 0.910 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2025 | 14 | 0.900 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2026 | 117 | 0.900 |
Why?
|
| Ablation Techniques | 1 | 2025 | 26 | 0.890 |
Why?
|
| Atrial Appendage | 1 | 2026 | 41 | 0.890 |
Why?
|
| Ultrasonography, Interventional | 1 | 2026 | 124 | 0.850 |
Why?
|
| Anticoagulants | 4 | 2024 | 529 | 0.840 |
Why?
|
| Perioperative Care | 2 | 2024 | 87 | 0.830 |
Why?
|
| Syncope, Vasovagal | 1 | 2023 | 8 | 0.790 |
Why?
|
| High-Frequency Jet Ventilation | 1 | 2022 | 3 | 0.720 |
Why?
|
| High-Frequency Ventilation | 1 | 2022 | 6 | 0.710 |
Why?
|
| Defibrillators, Implantable | 1 | 2024 | 273 | 0.680 |
Why?
|
| Patient Discharge | 1 | 2022 | 521 | 0.570 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2023 | 35 | 0.560 |
Why?
|
| Treatment Outcome | 7 | 2026 | 5818 | 0.420 |
Why?
|
| Risk Assessment | 3 | 2026 | 2113 | 0.320 |
Why?
|
| Time Factors | 3 | 2026 | 3777 | 0.310 |
Why?
|
| Risk Factors | 3 | 2026 | 5466 | 0.250 |
Why?
|
| Humans | 13 | 2026 | 65635 | 0.250 |
Why?
|
| Propensity Score | 1 | 2026 | 192 | 0.220 |
Why?
|
| Administration, Oral | 2 | 2024 | 371 | 0.220 |
Why?
|
| Action Potentials | 1 | 2025 | 113 | 0.220 |
Why?
|
| Hematoma | 1 | 2024 | 85 | 0.210 |
Why?
|
| Hypotension | 1 | 2024 | 51 | 0.200 |
Why?
|
| Heart Rate | 1 | 2025 | 334 | 0.200 |
Why?
|
| Recurrence | 1 | 2025 | 664 | 0.200 |
Why?
|
| Age Factors | 2 | 2026 | 1592 | 0.190 |
Why?
|
| Inpatients | 1 | 2026 | 322 | 0.190 |
Why?
|
| Body Surface Potential Mapping | 2 | 2013 | 4 | 0.190 |
Why?
|
| Equipment Design | 2 | 2022 | 373 | 0.190 |
Why?
|
| Patient Safety | 1 | 2026 | 281 | 0.190 |
Why?
|
| Heart Conduction System | 2 | 2013 | 50 | 0.190 |
Why?
|
| Databases, Factual | 1 | 2026 | 888 | 0.190 |
Why?
|
| Equipment Failure | 1 | 2022 | 69 | 0.180 |
Why?
|
| Middle Aged | 8 | 2026 | 18434 | 0.180 |
Why?
|
| Tidal Volume | 1 | 2022 | 41 | 0.180 |
Why?
|
| Aged | 6 | 2026 | 15087 | 0.170 |
Why?
|
| Postoperative Complications | 3 | 2026 | 1335 | 0.170 |
Why?
|
| Hypertension | 2 | 2024 | 616 | 0.150 |
Why?
|
| Male | 8 | 2026 | 31285 | 0.150 |
Why?
|
| Female | 8 | 2026 | 34298 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2022 | 3328 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2026 | 6948 | 0.140 |
Why?
|
| Pandemics | 1 | 2022 | 691 | 0.130 |
Why?
|
| Stroke | 1 | 2026 | 1220 | 0.130 |
Why?
|
| United States | 2 | 2026 | 8166 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2026 | 5656 | 0.120 |
Why?
|
| Thiophenes | 1 | 2014 | 31 | 0.100 |
Why?
|
| Morpholines | 1 | 2014 | 91 | 0.100 |
Why?
|
| Cardiac Catheters | 1 | 2012 | 13 | 0.090 |
Why?
|
| Electrodes, Implanted | 1 | 2012 | 38 | 0.090 |
Why?
|
| Heart Atria | 1 | 2013 | 137 | 0.090 |
Why?
|
| beta-Alanine | 1 | 2012 | 8 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2012 | 55 | 0.090 |
Why?
|
| Registries | 2 | 2014 | 933 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2012 | 193 | 0.080 |
Why?
|
| Adult | 2 | 2025 | 17508 | 0.080 |
Why?
|
| Warfarin | 1 | 2012 | 125 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 300 | 0.080 |
Why?
|
| Software | 1 | 2013 | 401 | 0.070 |
Why?
|
| Algorithms | 1 | 2013 | 1051 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2014 | 593 | 0.060 |
Why?
|
| Angiotensinogen | 1 | 2024 | 3 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 183 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 745 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2024 | 535 | 0.040 |
Why?
|
| RNA Interference | 1 | 2024 | 647 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 427 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 1172 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2026 | 2730 | 0.040 |
Why?
|
| Hospitalization | 1 | 2026 | 1403 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 1715 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2496 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2014 | 21 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2014 | 19 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 38 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 79 | 0.020 |
Why?
|
| Dabigatran | 1 | 2012 | 20 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 858 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 397 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 165 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 102 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 286 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 995 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 555 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 513 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1432 | 0.020 |
Why?
|
| Animals | 1 | 2012 | 21450 | 0.010 |
Why?
|